Oxbryta in HOPE-KIDS Meeting ‘Urgent Need’ of Children, Ages 4-11

Oxbryta in HOPE-KIDS Meeting ‘Urgent Need’ of Children, Ages 4-11

297008

Oxbryta in HOPE-KIDS Meeting ‘Urgent Need’ of Children, Ages 4-11

In children with sickle cell disease (SCD), ages 4–11, weight-based doses of Oxbryta (voxelotor) result in similar rises in hemoglobin levels and reductions in red blood cell destruction (hemolysis) to those observed in older patients at the approved dose, six-month data from the ongoing Phase 2 HOPE-KIDS 1 trial suggest. “The hematologic [blood-related] responses for these children closely follows the response found in adults receiving Oxbryta,” Robert Clark Brown, MD, PhD, a pediatric hematologist and…

You must be logged in to read/download the full post.